BiotechTube

INKmune

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cancer

Conditions

Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC

Trial Timeline

Nov 30, 2023 → Sep 10, 2025

NCT ID
NCT06056791

About INKmune

INKmune is a phase 1/2 stage product being developed by INmune Bio for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT06056791. Target conditions include Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT06056791Phase 1/2Completed
NCT05933070Phase 1Terminated

Competing Products

20 competing products in Cancer

See all competitors
ProductCompanyStageHype Score
E7389EisaiPhase 1
33
VeliparibAbbViePhase 2
52
AK-105AkesoPhase 1
32
XL820ExelixisPhase 1
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
23
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52
LY3300054 + PrexasertibEli LillyPhase 1
33
BBP-398 with nivolumabBridgeBio PharmaPhase 1
30
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
52
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
52
SelpercatinibEli LillyPre-clinical
23
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
36
NBTXR3NanobiotixPhase 1/2
36

Other Products from INmune Bio

INB03 + PlaceboPhase 2/3
57
XPro1595Phase 2
44
XPro1595 + PlaceboPhase 2
44
XPro1595 + PlaceboPhase 2
44
XPro1595Phase 1
25